Cargando…
Determination of Serum Progranulin in Patients with Untreated Familial Hypercholesterolemia
Background: Familial hypercholesterolemia (FH) is an autosomal dominant trait characterized by elevated LDL-C concentrations and is associated with an increased risk of premature atherosclerosis. Progranulin (PGRN) is a multifunctional protein that is known to have various anti-atherogenic effects....
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032136/ https://www.ncbi.nlm.nih.gov/pubmed/35453521 http://dx.doi.org/10.3390/biomedicines10040771 |
_version_ | 1784692566708453376 |
---|---|
author | Nádró, Bíborka Lőrincz, Hajnalka Juhász, Lilla Szentpéteri, Anita Sztanek, Ferenc Varga, Éva Páll, Dénes Paragh, György Harangi, Mariann |
author_facet | Nádró, Bíborka Lőrincz, Hajnalka Juhász, Lilla Szentpéteri, Anita Sztanek, Ferenc Varga, Éva Páll, Dénes Paragh, György Harangi, Mariann |
author_sort | Nádró, Bíborka |
collection | PubMed |
description | Background: Familial hypercholesterolemia (FH) is an autosomal dominant trait characterized by elevated LDL-C concentrations and is associated with an increased risk of premature atherosclerosis. Progranulin (PGRN) is a multifunctional protein that is known to have various anti-atherogenic effects. To date, the use of serum PGRN in patients with FH has not been studied. Methods: In total, 81 untreated patients with heterozygous FH (HeFH) and 32 healthy control subjects were included in this study. Serum PGRN, sICAM-1, sVCAM-1, oxLDL and TNFα concentrations were determined by ELISA. Lipoprotein subfractions were detected by Lipoprint. We diagnosed FH using the Dutch Lipid Clinic Network criteria. Results: We could not find a significant difference between the PGRN concentrations of the HeFH patients and controls (37.66 ± 9.75 vs. 38.43 ± 7.74 ng/mL, ns.). We found significant positive correlations between triglyceride, TNFα, sVCAM-1, the ratio of small HDL subfraction and PGRN, while significant negative correlations were found between the ratio of large HDL subfraction and PGRN both in the whole study population and in FH patients. PGRN was predicted by sVCAM-1, logTNFα and the ratio of small HDL subfraction. Conclusions: The strong correlations between HDL subfractions, inflammatory markers and PGRN suggest that PGRN may exert its anti-atherogenic effect in HeFH through the alteration of HDL composition and the amelioration of inflammation rather than through decreasing oxidative stress. |
format | Online Article Text |
id | pubmed-9032136 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90321362022-04-23 Determination of Serum Progranulin in Patients with Untreated Familial Hypercholesterolemia Nádró, Bíborka Lőrincz, Hajnalka Juhász, Lilla Szentpéteri, Anita Sztanek, Ferenc Varga, Éva Páll, Dénes Paragh, György Harangi, Mariann Biomedicines Article Background: Familial hypercholesterolemia (FH) is an autosomal dominant trait characterized by elevated LDL-C concentrations and is associated with an increased risk of premature atherosclerosis. Progranulin (PGRN) is a multifunctional protein that is known to have various anti-atherogenic effects. To date, the use of serum PGRN in patients with FH has not been studied. Methods: In total, 81 untreated patients with heterozygous FH (HeFH) and 32 healthy control subjects were included in this study. Serum PGRN, sICAM-1, sVCAM-1, oxLDL and TNFα concentrations were determined by ELISA. Lipoprotein subfractions were detected by Lipoprint. We diagnosed FH using the Dutch Lipid Clinic Network criteria. Results: We could not find a significant difference between the PGRN concentrations of the HeFH patients and controls (37.66 ± 9.75 vs. 38.43 ± 7.74 ng/mL, ns.). We found significant positive correlations between triglyceride, TNFα, sVCAM-1, the ratio of small HDL subfraction and PGRN, while significant negative correlations were found between the ratio of large HDL subfraction and PGRN both in the whole study population and in FH patients. PGRN was predicted by sVCAM-1, logTNFα and the ratio of small HDL subfraction. Conclusions: The strong correlations between HDL subfractions, inflammatory markers and PGRN suggest that PGRN may exert its anti-atherogenic effect in HeFH through the alteration of HDL composition and the amelioration of inflammation rather than through decreasing oxidative stress. MDPI 2022-03-25 /pmc/articles/PMC9032136/ /pubmed/35453521 http://dx.doi.org/10.3390/biomedicines10040771 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Nádró, Bíborka Lőrincz, Hajnalka Juhász, Lilla Szentpéteri, Anita Sztanek, Ferenc Varga, Éva Páll, Dénes Paragh, György Harangi, Mariann Determination of Serum Progranulin in Patients with Untreated Familial Hypercholesterolemia |
title | Determination of Serum Progranulin in Patients with Untreated Familial Hypercholesterolemia |
title_full | Determination of Serum Progranulin in Patients with Untreated Familial Hypercholesterolemia |
title_fullStr | Determination of Serum Progranulin in Patients with Untreated Familial Hypercholesterolemia |
title_full_unstemmed | Determination of Serum Progranulin in Patients with Untreated Familial Hypercholesterolemia |
title_short | Determination of Serum Progranulin in Patients with Untreated Familial Hypercholesterolemia |
title_sort | determination of serum progranulin in patients with untreated familial hypercholesterolemia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032136/ https://www.ncbi.nlm.nih.gov/pubmed/35453521 http://dx.doi.org/10.3390/biomedicines10040771 |
work_keys_str_mv | AT nadrobiborka determinationofserumprogranulininpatientswithuntreatedfamilialhypercholesterolemia AT lorinczhajnalka determinationofserumprogranulininpatientswithuntreatedfamilialhypercholesterolemia AT juhaszlilla determinationofserumprogranulininpatientswithuntreatedfamilialhypercholesterolemia AT szentpeterianita determinationofserumprogranulininpatientswithuntreatedfamilialhypercholesterolemia AT sztanekferenc determinationofserumprogranulininpatientswithuntreatedfamilialhypercholesterolemia AT vargaeva determinationofserumprogranulininpatientswithuntreatedfamilialhypercholesterolemia AT palldenes determinationofserumprogranulininpatientswithuntreatedfamilialhypercholesterolemia AT paraghgyorgy determinationofserumprogranulininpatientswithuntreatedfamilialhypercholesterolemia AT harangimariann determinationofserumprogranulininpatientswithuntreatedfamilialhypercholesterolemia |